-+ 0.00%
-+ 0.00%
-+ 0.00%

Rhelion unit Filament Health plans stability program for IBEX011 ibogaine candidate

PUBT·09/10/2026 12:00:28
Listen to the news
Rhelion unit Filament Health plans stability program for IBEX011 ibogaine candidate
  • Filament Health, a wholly owned unit of Rhelion Life Sciences, began planning a stability program for IBEX011, a naturally derived ibogaine candidate.
  • Program aims to support expected demand for GMP-grade, standardized ibogaine for regulated clinical research.
  • IBEX011 is a Nagoya Protocol-compliant GMP total-alkaloid extract of Tabernanthe iboga, produced using Filament’s proprietary extraction platform.
  • Filament previously completed a Nagoya Protocol-compliant import of Tabernanthe iboga root from Gabon to its Metro Vancouver R&D facility in May 2023.
  • IBEX011 remains investigational, with no authorization for clinical trials and no regulatory approval for any indication.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhelion Life Sciences Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609100755NEWSFILECNPR____20260910_313819_1) on September 10, 2026, and is solely responsible for the information contained therein.